Therapeutic Use of Artificially Generated Mononegavirales Defective Interfering Particles (DIP)

This technology includes using defective interfering (DI) genomes as a therapeutic against various mononegavirales. DI genomes are defective versions of the wildtype viral genome, incapable of replicating by itself but able to interfere with replication of the wildtype virus. We developed both a system to identify and characterize multiple naturally occurring henipaviruses Nipah (NiV) DI genomes species, and a methodology to artificially produce high titer stocks of virions containing these DI genomes, termed DI particles (DIPs).

Plasmodium falciparum Strains for Therapeutic, Diagnostic, and Commercial Research Use

This technology includes plasmodium falciparum parasites (PH1, Benin, FCQ79, Santa Lucia and Borneo) which have all been isolated from infected persons from various geographic locations and have been modified/adapted for growth in the laboratory for multiple uses. Plasmodium falciparum strain W2 is a parasite clone from a parasite isolate called Indochina III/CDC which in turn originated from a patient in Laos infected with chloroquine-resistant parasites. Gametocytes from W2 can be grown experimentally and used in experimental infection of chimpanzees and aotus monkeys.

Novel Reassortant Mammalian Orthoreovirus Isolate for the Development of Vaccines and Diagnostic Tools

This technology includes a novel, isolated reassortant mammalian Orthoreovirus (MRV) isolated from pigs with neurological symptoms, for use in the development of vaccines and diagnostic tests. This isolate has S1 gene from MRV1 closed to bovine isolated, M2 gene from MRV2 and other 8 genes from MRV3 based on full-genome sequence analysis. MRV3 has been reported and isolated from the US pigs with diarrhea symptom. Compared to the reported swine MRV3 isolates that cause diarrhea in pigs, the novel reassortant MRV causes neurological disease in pigs.

Development of LEAPS Technology in Enhancing Immune Response Against Influenza Virus Infection

The Ligand Epitope Antigen Presentation System (LEAPS) represents a breakthrough in immunotherapeutic technology developed by CEL-SCI Corporation. This technology employs a novel approach to boost the immune system's response to influenza, aiming to treat, manage, or even prevent the illness. By combining LEAPS with a specific peptide from the influenza virus, and administering it intravenously in mice, there's a marked improvement in the immune system's ability to fight off the virus.

Methods of making and using dopamine receptor selective antagonists/partial agonists

Dopamine is a major neurotransmitter in the central nervous system and among other functions is directly related to the rewarding effects of drugs of abuse.  Dopamine signaling is mediated by D1, D2, D3, D4 and D5 receptors.  The dopamine D3 receptor is a known target to treat a variety of neuropsychiatric disorders, including substance use disorders (e.g. cocaine and opioid), schizophrenia and depression.

Enhancing Immunogenicity and Protection in Calves

The discovery outlined in the Employee Discovery and Invention Report represents a significant advancement in veterinary vaccine technology, specifically targeting the bovine respiratory syncytial virus (bRSV). This innovation involves a "DS2" version of the bRSV F vaccine, which has been engineered to enhance immunogenicity through a prefusion-stabilized form of the F protein, absent of the fusion peptide and reinforced by cavity-filling mutations and inter-protomer disulfides.

A Broadly Protective Human Antibody for GI Genogroup Noroviruses

Norovirus is a leading cause of vomiting, diarrhea, and foodborne illness worldwide, with 700 million cases and 200,000 deaths occurring each year. Despite decades of work in the field, there are no preventive or therapeutic strategies specifically approved for even the most prevalent forms of human norovirus (i.e., GI, GII genogroups), which are highly contagious and carry an increased risk of severe complications in children, older adults, and those with immunocompromising conditions.